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. Overview
Currently, several specific direct-acting antiviral agent (DAA)
ptions are available to fight hepatitis C virus infection. Many
fforts have been dedicated to the identification of new thera-
eutic strategies aimed at targeting virus–host cell interactions. A
ommon mechanism for many RNA viruses that replicate in the
ytoplasm is the alteration of the cell environment by deregulation
f oxidative stress and antioxidant systems. Because antioxidants
efend cells from damage caused by reactive oxygen species (ROS),
hey represent interesting molecules to fight infectious diseases.
ased on the foregoing, the use of antioxidants in viral hepatitis
nfection as antiviral adjuvants generated much controversy some
ears ago, and yet to date, we still do not know if they could be
eneficial to favor an adequate cellular response in the presence
f specific antivirals. Here, we will provide some recent data that
ill allow us to have a better understanding about the relationship
etween HCV replication, new DAAs, oxidative stress and antioxi-
ant compounds.
. HCV antiviral optionsWe  remember in 2011 the birth of a new era in antivirals, when
he first generation of DAAs against HCV was reported. Since then,
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reativecommons.org/licenses/by-nc-nd/4.0/).we have learned a lot about the virology of HCV; however, we  still
have doubts about the basic mechanisms that the cell uses to coun-
teract the viral attack. These mechanisms include modulation of
apoptosis, oxidative stress, stress of the endoplasmic reticule, cell
communication, and others. Several specific antiviral options are
currently available to fight hepatitis C virus infection. Specific anti-
HCV drugs include protease inhibitors (such as Simeprevir), NS5A
inhibitors (such as daclatasvir and ledipasvir) and RNA polymerase
inhibitors (such as Sofosbuvir) which jointly block the release of
virions from infected cells [1].
3. Oxidant/antioxidant defense network induced by virus
It is well known that oxidative stress is altered during viral infec-
tions. This can be caused by the decrease in antioxidant defenses
and the increase in reactive oxygen species (ROS) production in dif-
ferent cell compartments [2]. HCV can modulate intracellular redox
sensitive signaling pathways involved in several cell functions in
order to promote viral replication and pathogenesis. In particu-
lar, several papers have reported that ROS and reactive nitrogen
species (RNS) contribute to the development of HCV virus-induced
pathogenesis in the liver. The emergence of strains resistant to HCV
antiviral agents highlights the need to search for new drugs that
act on new molecular targets [3]. An interesting approach should
be targeting interactions between the virus and the host cell that
could reduce viral replication and ameliorate cell functions. Phys-
iological levels of ROS mediate cell signaling, while upregulated
levels of ROS are involved in oxidative damage to cellular compo-
nents and cell death [2]. Under this context, antioxidant enzymatic
systems and natural compounds are triggered to mitigate or resolve
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his situation conforming an “antioxidant defense network”. In such
 way, supplementation with antioxidants has been suggested to
inimize the infection disease effects.
. Antioxidants to assist the antiviral approach
Antioxidants represent interesting molecules that have been
roposed for the treatment of several viral infections. In 2006,
riel et al. proposed the prophylactic use of nutritional supplement
ith antioxidants to counteract general pathogenic mechanisms
nderlying virus infection in humans [4]. Recently, Gonç alves et al.
roposed orange juice as a dietary source of antioxidants for
atients with hepatitis C under antiviral therapy. They demon-
trated that orange juice was a convenient food in the diet of
atients due to the increase in antioxidant capacity and decreased
nflammation and cholesterol in blood serum, in addition to main-
aining body mass, which protects against the harmful effects
aused by C virus chronic hepatitis (CHC) [5]. Several authors,
ncluding our research group, have reported that natural and phar-
acological compounds with antioxidant capacity significantly
ecrease the replication of several viruses [6–9]. Antioxidant ther-
py could be criticized because it involves a variety of unrelated
rugs, rather than the specific or magic one used in today’s phar-
acotherapy. However, there is a scientific basis for this strategy
s antiviral therapy.
It would be reasonable to increase the antioxidant capacity
f the cell using exogenous compounds of synthetic origin or
he diet, thus enhancing cell defenses against free radical forma-
ion. Natural antioxidants present in fruit, vegetables and marine
nimals, including vitamins C and E, astaxanthin, xanthophyll
arotenoid, vegetal carotenoids, minocycline, arctigenin, fenofi-
rate, curcumin, and polyphenols (e.g. flavonoids), are currently
onsidered to be beneficial [10]. It is reported that antioxidant
nzyme levels (superoxide dismutase (SOD), catalase, and glu-
athione peroxidase) were increased in rats upon treatment with
staxanthin [11]. The antiviral activity of rosmarinic acid and lute-
lin is shown to be due to their high antioxidant, anti-inflammatory
nd neuroprotective potential. However, many controversies sur-
ound the effects of these compounds in experimental models, and
heir real benefits are still a matter of debate.
It is not known if different agents with antiviral activity can
nterfere with the modulation of the cellular redox state induced
y HCV and decrease viral replication. Recent reports of antioxi-
ant compounds highlight their antiviral activity against HCV and
romote them as anti-HCV co-adjuvants that can improve treat-
ent effectiveness, shorten the treatment period, and reduce the
verall cost of therapy. In Table 1 , relevant antioxidants proposed
s anti-HCV agents are described. Clearly, this does not obviate the
urther search for drugs that specifically interfere with viral repli-
ation. This viewpoint describes the structure and mechanism of
ction of the main antioxidants studied as antiviral agents.
.1. Epigallocatechin-3-gallate ((−)-EGCG)
This is the most abundant and bioactive catechin in green tea. It
ossesses antiviral activity because it can enhance in vitro synthe-
ized HCV dsRNAs-induced innate immune responses in both HCV
FH-1-infected and -uninfected Huh7 cells. In cells treated with
GCG before HCV dsRNAs stimulation, the HCV dsRNAs induced
he expression of IFN-1, RIG-I, TLR3 and several antiviral inter-
eron sensitive genes (ISG15, MxA), thus inhibiting hepatitis C virus
eplication in hepatocytes [12]. The controversy remains regarding
he mechanisms involved that are triggered by EGCG. There is no
vidence about the modulation of ROS during these experiments
nd clinical studies are still missing. Hepatology 18 (2019) 410–415 411
4.2. Vitamins C, D and E
Vitamin C protects cell components from free radical damage
by reducing water-soluble radicals, scavenging lipid-peroxidation-
derived radicals, or reducing tocopherol radicals to tocopherol.
Currently, vitamin D deficiency is being investigated in CHC
patients. A randomized double-blinded, placebo-controlled trial
was performed to assess the dynamic changes in serum fibrogenic
cytokines/enzymes in CHC patients with vitamin D deficiency after
short-term supplementation with vitamin D [10]. Regarding vita-
min  E, the principal lipid soluble chain-breaking antioxidant in
mitochondria, microsomes, and lipoproteins, it has been demon-
strated that disease progression induced by partial hepatectomy
is substantially attenuated by this vitamin [10,13,14]. There are
several reports with conflicting or non-reproducible results using
these vitamins; therefore, there is still controversy on the useful-
ness or causality correlation between supplementation and viral
load.
4.3. Glutathione (GSH) restoring agents and analogues
It has been shown that the replenishment of intracellular GSH
obtained with the administration of GSH, a GSH  derivative or a GSH
precursor inhibited the replication of several viruses in vitro and
in vivo [15]. We  previously reported that S-adenosylmethionine
increases the synthesis of GSH in Huh7 cells with and without
non-structural HCV protein expression, and in the latter, replication
decreases [7]. In fact, the oxidative environment established by GSH
depletion during viral infection is needed to modify the expression
of several antioxidant systems, thus disturbing the redox balance
and favoring viral replication and maturation.
4.4. Quercetin
Quercetin is an antioxidant flavonoid. In vitro treatment of HCV
infection with quercetin decreased intracellular viral accumulation
and infectious particle production. It has been shown that quercetin
inhibits viral protein production independently of viral genome
replication. In conclusion, quercetin significantly decreases viral
genome replication, the production of infectious HCV particles and
the specific infectivity of the newly produced viral particles [16].
Additionally, dihydroquercetin has been shown to be beneficial as
a hepatoprotective substance in the treatment of toxic hepatitis
and liver fibrosis by enhancing antioxidant enzyme activity and
decreasing the pro-oxidant effect. Nevertheless, clinical trial evi-
dence is still missing.
4.5. S-adenosylmethionine (SAM)
Administration of SAM to non-responding patients infected
with HCV, showed beneficial effects in combination with PEG-IFN
and ribavirin. Our recent results indicate that there is a combi-
nation of actions regarding the molecular mechanisms of SAM
on HCV replication. We  have found that administration of SAM
to HCV-expressing cells modulates the antioxidant defense sys-
tems at the transcriptional and translational level (SOD1, SOD2
and Thioredoxin 1). Also, we  identified that the biosynthesis of
GSH in the presence of SAM is increased in short periods of time.
In addition, we  found that MAT1/MAT2 turnover is switched in
the presence of SAM. MAT1 is the enzyme responsible for the
conversion of methionine to S-adenosylmethionine, and it is down-
regulated in hepatocarcinoma and liver diseases. But still we  need



















Relevant antioxidants proposed as anti-HCV agents.
Antioxidant Described function Study
model









Inhibition of mTOR (invasion and metastasis
blocking)
More evidence is needed in order to conclude





Favors vitamins and minerals intake,
antioxidant, prevents hepatitis and accelerates
wound healing.
Further randomized, placebo-armed studies
need to be performed in order to confirm
whether supplementation of vitamins
analogues improve response. There is still
controversy on their usefulness.
Vitamin D Fat-soluble antioxidant In vitro and
in vivo
Potent antioxidant reduces lipid oxidation and
stimulates enzymes that protects against
oxidation.
Further randomized, placebo-armed studies
need to be performed in order to confirm
whether supplementation of vitamins
analogues improve response. There is still
controversy on their usefulness.
Vitamin E Fat-soluble antioxidant In vitro and
in vivo
Lipid antioxidant Further randomized, placebo-armed studies
need to be performed in order to confirm
whether supplementation of vitamins
analogues improve response. There is still

























Antioxidant Described function Study
model
Reported mechanism Controversy Chemical structure
Quercetin Antioxidant flavonoid In vitro It can bind hormone transporting enzymes and
DNA. Also it can chelate metal ions, catalyze
electron transport and debug free radicals.
There is promising evidence in vitro but there








SAM participates in cell growth and repair. It
also collaborates in several hormone syntheses.
Further experiments in patients are needed.









In vitro PDTC participates in metal chelation, cellular
cycle stop at G1 phase and prevention of nitric
oxide synthase induction.
PDTC prevents in vivo expression of
pro-inflammatory cytokines by inducing
RCAN1 expression.
There is no clinical assessment yet.
Gallic acid (GA) Phenolic acid,
antioxidant
In vitro Weak inhibitor of carbonic anhydrase. There are just a few reports in vitro and clinical






Protects several tissues and organs against
chemical injuries. Hepatoprotector agent.
Antioxidant.
There are several reports of the usage of this











MitoQ10 attenuates specific oxidative damage
of mitochondria; it can be pro-oxidant and
pro-apoptotic, because its quinone group can
participate in redox pathways and the
superoxide production.
The usage as an antifibrotic is more evident
than as an antiviral.
Zinc Biometal, enzymatic
co-factor
In vivo Zinc is part of the enzyme superoxide
dismutase, which is responsible for eliminating
free radicals. Protects the DNA and de cellular
nucleus.
More evidence about the usage of this
compound combined with the new DAAs is
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.6. Pyrrolidine dithiocarbamate (PDTC)
PDTC is a thiol-containing molecule that can function as anti-
xidant compound depending on the experimental conditions. The
ntioxidant properties of PDTC are attributed to its ability to scav-
nge radicals, to chelate ions, and to alter ROS metabolism. PDTC is
lso able to regulate antioxidant enzyme gene expression (MnSOD,
eme oxygenase-1 and -glutamyl-cysteine synthetase [17]) and
nhibit NF-B. In addition, PDTC is able to suppress ROS accumu-
ation induced by influenza virus infection [18]. There is in vitro
vidence about the antiviral effect of PDTC against HCV [9]; how-
ver, further in vivo studies are needed.
.7. Gallic acid (GA)
Gallic acid is a phenolic compound found in natural sources. It
as several therapeutic health effects for many diseases including
ancer, neurodegenerative diseases, diabetes, cardiovascular dis-
ases and viral infectious diseases [19]. Our group has previously
eported that GA downregulated NS5A-HCV protein expression
around 55%) and HCV-RNA levels (nearly 50%) compared with
ntreated cells. Additionally, GA treatment also decreased ROS lev-
ls in cells expressing HCV proteins [6]. These findings suggest the
ossibility that the antioxidant capacity of GA could contribute to
he mechanism(s) involved in the downregulation of HCV replica-
ion in hepatoma cells; however, further experiments are needed
o confirm these findings.
.8. Silymarin
Silibinin is the main component of milk thistle (silymarin) and
as strong antioxidant and antifibrotic properties. This natural
ompound inhibits radical formation, binds some radical species
scavenger), interferes with lipid peroxidation of membranes, and
ncreases the intracellular content of scavengers. An intravenous
dministration of silibinin in nonresponders showed a decrease in
he HCV-RNA level [20].
.9. Acetylsalicylic acid (ASA)
It has been documented that sodium salicylate and ASA inhibit
he replication of flaviviruses. In 2008, Trujillo Murillo et al. [8]
eported that ASA exhibits anti-HCV properties because of its
nhibitory effect on COX-2 expression, which is mediated in part
y the activation of mitogen-activated protein kinase/extracellular
ignal-regulated kinase kinase 1/2 (MEK1/2)/p38 MAPKs. These
ndings suggest the possibility that ASA could be an adjuvant in
he treatment of HCV infection.
.10. Mitoquinone
Mitoquinone (MitQ) is a potent antioxidant that binds coen-
yme Q10 (known as ubiquinone) to a triphenylphosphonium
ation. The cation causes the attached antioxidant to accumulate
everal-hundred fold within mitochondria in vivo following oral
dministration, protecting the cell from oxidative damage. MitQ
reatment demonstrated reduced serum aminotransferase in HCV
nfected patients. Thus, MitQ is outlining more as an antifibrotic
gent than an antiviral agent [21].
.11. ZincPolaprezinc (a combination of zinc and l-carnosine), an antiox-
dant, has been studied as an adjuvant to IFN in the treatment
f chronic HCV infection in many studies. There are a number Hepatology 18 (2019) 410–415
of potential mechanisms of the beneficial effects of zinc includ-
ing reduction of hepatic fibrosis, a decrease in ferritin, antioxidant
activity, and improvement in hepatic encephalopathy with reduced
levels of oxidative stress products such as malondialdehyde (MDA),
4-hydroxyalkenals (HAE), and 8-hydroxydeoxyguanine in plasma.
Zinc has also been shown to negatively affect HCV replication jus-
tifying its use for treatment of HCV infection [22].
5. New strategies for inhibiting ROS production
ROS production is carried out in several cellular compartments,
mainly ER and mitochondria. Several enzymes in the cells are able
to produce ROS among which xanthine oxidase, cytochrome P450
oxidase, uncoupled nitric oxide synthase, NADPH (nicotinamide
adenine dinucleotide phosphate) oxidases, and the mitochon-
drial electron transport chain are involved. However, only NADPH
oxidases produce ROS as their primary and unique function. Antiox-
idants act in four different ways to fight viral infection: (1) they
impair mechanisms involved in HCV replication, (2) improve liver
enzyme levels, (3) protect against liver cell damage and (4) render
interferon anti-viral therapy more effective. In fact, triple antiox-
idant therapies are on the rise, which include alpha-lipoic acid,
silymarin and selenium in suppressing HCV-induced liver disease,
when used together with vitamins C and E, and with a healthy diet
and exercise.
6. Controversy
The evidence on whether antioxidant supplements are effec-
tive in the treatment of liver diseases is contradictory. Based on
the conducted randomized clinical trials, convincing evidence that
beta-carotene, vitamin A, vitamin C, and vitamin E or their combi-
nations are beneficial for the treatment of alcoholic, autoimmune,
hepatitis B or hepatitis C virus liver diseases or liver cirrhosis could
not be found, contrary to in vitro results. MitQ,  on the other hand,
has not been related with a decrease in viral load but with antifi-
brotic features. There are some antioxidants such as PDTC that have
not been tested in HCV infected patients. It has a potent negative
effect in HCV expression in vitro, but the data in vivo has still not
been assessed. SAM was  used as adjuvant treatment along with
IFN and ribavirin in non-responding HCV patients in 2011; how-
ever, since then, and besides the reports in vitro, there is only one
clinical study and this compound was  not reported to be assessed
in combination with the new DAAs. Nevertheless, all those agents
still have promising features to fight CHC and more importantly as
adjuvant therapy for the remaining fibrosis and cirrhosis.
All these data together suggest that antioxidants can effectively
improve the response of HCV-infected patients, decreasing oxida-
tive and nitrosative stress in liver injury, then ultimately improving
inflammation and fibrosis progression. Some investigators think
that although it is worth testing these antioxidant drugs in future
clinical trials, they emphasize the need for investigation on the
effects of different antioxidants on HCV replication before their use
as adjunctive therapy.
In fact, HCV proteins, for their own  replication, manipulate sev-
eral intracellular signaling pathways; and some are finely regulated
by the cellular redox state. The role of HCV-induced oxidative stress,
cellular protein interplay, and molecular mechanisms involved
remain undefined. With the current findings about the dual func-
tion of the balance of oxidative stress induced by the virus and
the host cell and the future concepts available, it may  be possi-
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. Summary and conclusions
HCV infection is associated with oxidative/nitrosative stress.
uring the infection many damaging processes are triggered; lipid
eroxidation, oxidative DNA damage, protein oxidation, and also
 decrease in the antioxidant capacity of liver cells have been
eported. Generation of oxidative stress by HCV infection is esti-
ated to originate from mitochondrial dysfunction of hepatocytes.
hether the antioxidants may  help to alleviate HCV infection
ould depend on the oxidative status within the cell or tissue,
nd also on the dosage and the type of antioxidant used. Contro-
ersy in the use of antioxidants during antiviral therapy could be
elated to the fact that an excess of some antioxidants within the
ell is reported to be harmful or beneficial depending on the stage
f infection. There are a lot of clinical studies in patients with dif-
erent scenarios. In this case, a systematic review could be useful
o compare results with all DAA-treated patients.
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